02630nam 2200529z- 450 991063997780332120250204145854.097819203829711920382976(CKB)4100000009513077(oapen)https://directory.doabooks.org/handle/20.500.12854/96062(Perlego)3511834(EXLCZ)99410000000951307720220518d2017 uy |engurmn|---annantxtrdacontentcrdamediacrrdacarrierCommunion ecclesiology in a racially polarised South Africa /Kelebogile T. ResaneBloemfonteinUJ Press20171 electronic resource (285 p.)9781920382964 1920382968 The biblical understanding of communion -- The historical roots of communion ecclesiology -- Traditional and contemporary definitions of communion ecclesiology -- African ubuntu and communion ecclesiology -- Building the 'laager': the South African Reformed theology's journey towards the communion -- Matlo g ša mabapi -- an injury to one is an injury to all -- The forgotten golden nuggets -- The pastoral application of communion ecclesiology -- Now, our eschatological journey.Communion Ecclesiology by Dr. K.T. Resane explores the concept of a communion ecclesiology in South Africa. The book provides the reader with a comprehensive overview of the concept in the Bible, in history and in different church traditions including the African Initiated Churches. The book also focuses on the different cultural groups in South Africa as they were organised within theological traditions. - Prof. S.D. Snyman, University of the Free StateChristian theologybicsscChurchHistoryReligionTheologyAfrican Independent ChurchesAfrikaanse Christelike Studente VereenigingcharismaticChristelike Studente AssosiasiehomothymadonInternational PentecostalEvangelical Fellowship of South Africabiblical understanding of communionhistorical roots of communion ecclesiologytraditional and contemporary definitions of communion ecclesiologyChristian theologyResane K. Thomas1780396BOOK9910639977803321Communion ecclesiology in a racially polarised South Africa4304311UNINA05893nam 2200433z- 450 991022004680332120210211(CKB)3800000000216309(oapen)https://directory.doabooks.org/handle/20.500.12854/50412(oapen)doab50412(EXLCZ)99380000000021630920202102d2017 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierIntellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and TreatmentFrontiers Media SA20171 online resource (179 p.)Frontiers Research Topics2-88945-045-7 Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer's disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90's and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer's disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.Research on the multiple aspects of cognitive impairment in Down syndrome (DS), from genes to behavior to treatment, has made tremendous progress in the last decade. The study of congenital intellectual disabilities such as DS is challenging since they originate from the earliest stages of development and both the acquisition of cognitive skills and neurodegenerative pathologies are cumulative. Comorbidities such as cardiac malformations, sleep apnea, diabetes and dementia are frequent in the DS population, as well, and their increased risk provides a means of assessing early stages of these pathologies that is relevant to the general population. Notably, persons with DS will develop the histopathology of Alzheimer's disease (formation of neuritic plaques and tangles) and are at high risk for dementia, something that cannot be predicted in the population at large. Identification of the gene encoding the amyloid precursor protein, its localization to chromosome 21 in the 90's and realization that all persons with DS develop pathology identified this as an important piece of the amyloid cascade hypothesis in Alzheimer's disease. Awareness of the potential role of people with DS in understanding progression and treatment as well as identification of genetic risk factors and also protective factors for AD is reawakening. For the first time since DS was recognized, major pharmaceutical companies have entered the search for ameliorative treatments, and phase II clinical trials to improve learning and memory are in progress. Enriched environment, brain stimulation and alternative therapies are being tested while clinical assessment is improving, thus increasing the chances of success for therapeutic interventions. Researchers and clinicians are actively pursuing the possibility of prenatal treatments for many conditions, an area with a huge potential impact for developmental disorders such as DS. Our goal here is to present an overview of recent advances with an emphasis on behavioral and cognitive deficits and how these issues change through life in DS. The relevance of comorbidities to the end phenotypes described and relevance of pharmacological targets and possible treatments will be considerations throughout.Intellectual Disabilities in Down Syndrome from Birth and throughout LifeNeurosciencesbicsscAlzheimer's diseaseDown SyndromeGABAIntellectual DisabilitiesLanguageprenatalTreatmentNeurosciencesMarie-Claude Potierauth1190734Roger H. ReevesauthBOOK9910220046803321Intellectual Disabilities in Down Syndrome from Birth and throughout Life: Assessment and Treatment3023978UNINA